Repros Therapeutics Inc (NASDAQ: RPRX)
Repros Therapeutics is having an incredible day in the market today, following up on gains we saw from the stock yesterday. The increases in value are happening for a very good reason. The company has been working on a treatment that’s designed to reduce excessive menstrual bleeding, and has announced positive data with regard to the treatment. Today, we’ll talk about the data that was released, how the market reacted to the news, and what we can expect to see from RPRX moving forward.
Trade smarter and make more money with Tradespoon!
RPRX Announces Positive Results Associated With Proellex
As mentioned above, Repros Therapeutics is having an incredible day in the market after the company made a big announcement yesterday. RPRX reported that vaginal administration of its leading candidate Proellex at doses of both 6mg and 12mg achieved significant reduction in excessive menstrual bleeding. This is a key symptom associated with uterine fibrosis. During the study, a total of 42 women with confirmed uterine fibroids were enrolled in three different arms of treatment. 13 women were enrolled for treatment with 6mg dosing. 15 women were enrolled for treatment with 12mg dosing, and 14 women were enrolled for treatment with a placebo. According to the results, the mean amount of blood loss for one menstrual cycle was 255 mL, 274 mL and 238 mL respectively.
In the announcement, RPRX explained that when a sufficient concentration of Prollex is achieved in circulation, amenorrhea is achieved. During the Phase 2b study, just over half of Proellex-treated patients became amenorrheic with no evidence of a dose effect. Perhaps more importantly, RPRX announced that the treatment was generally well tolerated and that women in the drug arms continued to exhibit levels of estradiol consistent with bone preservation.
How The Market Reacted To The News
When it comes to investing, one of the first things we learn when we start to work in the market is that the news causes movements. Positive news that is released with regard to any publicly-traded company is likely to lead to gains in the value of the stock associated with that company. Adversely, when negative news is released with regard to a publicly-traded company, we can expect to see declines. The news released by RPRX proved to be overwhelmingly positive. After all, evidence that a treatment under investigation is working and well tolerated is always good news. As such, we’re seeing strong gains on the value of the stock today. Currently (11:58), RPRX is trading at $1.34 per share after a gain of $0.52 per share or 63.59% thus far today.
What We Can Expect To See Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from RPRX. The reality is that the company’s advancements with regard to excessive menstrual bleeding are incredible. At the moment, Prollex seems like it is going to be a solid treatment for this problem. As such, investors are naturally excited about Repros Therapeutics, and are likely to remain excited. Based on the results that were released, I’m expecting Prollex to be approved by the FDA in the long run as a treatment for this condition. As such, this will likely become an incredibly profitable product under RPRX. All in all, things are looking great for the company and its investors.
Don’t waste your time! Click here to find winning trades in minutes!
What Do You Think?
Where do you think RPRX is headed and why? Let us know your opinion in the comments below!
[Image Courtesy of YouTube]